We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Teladoc (TDOC - Free Report) ended the recent trading session at $9.65, demonstrating a +2.33% change from the preceding day's closing price. This change outpaced the S&P 500's 0.19% loss on the day. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, lost 0.05%.
Shares of the telehealth services provider have appreciated by 16.85% over the course of the past month, outperforming the Medical sector's gain of 6.06%, and the S&P 500's gain of 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Teladoc in its upcoming earnings disclosure. The company's earnings report is set to go public on July 29, 2026. The company is predicted to post an EPS of -$0.24, indicating a 26.32% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $614.69 million, showing a 2.72% drop compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.92 per share and a revenue of $2.51 billion, signifying shifts of +19.3% and -0.92%, respectively, from the last year.
Any recent changes to analyst estimates for Teladoc should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Teladoc is carrying a Zacks Rank of #2 (Buy).
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 95, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Teladoc (TDOC) Gains As Market Dips: What You Should Know
Teladoc (TDOC - Free Report) ended the recent trading session at $9.65, demonstrating a +2.33% change from the preceding day's closing price. This change outpaced the S&P 500's 0.19% loss on the day. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, lost 0.05%.
Shares of the telehealth services provider have appreciated by 16.85% over the course of the past month, outperforming the Medical sector's gain of 6.06%, and the S&P 500's gain of 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Teladoc in its upcoming earnings disclosure. The company's earnings report is set to go public on July 29, 2026. The company is predicted to post an EPS of -$0.24, indicating a 26.32% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $614.69 million, showing a 2.72% drop compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.92 per share and a revenue of $2.51 billion, signifying shifts of +19.3% and -0.92%, respectively, from the last year.
Any recent changes to analyst estimates for Teladoc should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Teladoc is carrying a Zacks Rank of #2 (Buy).
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 95, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.